Comparative Pharmacology
Head-to-head clinical analysis: LANABIOTIC versus MYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANABIOTIC versus MYCHEL.
LANABIOTIC vs MYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LANABIOTIC is a lantibiotic that inhibits bacterial cell wall synthesis by binding to lipid II, a key precursor in peptidoglycan biosynthesis, thereby disrupting cell wall integrity and causing cell death.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
500 mg orally every 12 hours for 7-14 days.
Adults: 200 mg orally twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-30%.
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Category C
Category C
Antibiotic
Antibiotic